# Survodutide

*Also known as: Survodu, BI 456906*

Investigational dual GLP-1/glucagon receptor agonist for obesity and MASH; weekly injection.

## Overview

Survodutide (BI 456906) is an investigational dual agonist of the GLP-1 and glucagon receptors, designed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The dual mechanism is meant to combine GLP-1 appetite suppression and insulin effects with glucagon fat-burning and thermogenic action, potentially delivering greater weight loss than GLP-1-only drugs. It is a once-weekly injection with an estimated half-life of roughly six days and high bioavailability near 80%. Survodutide has a real and growing clinical evidence base. It is in advanced Phase 3 trials for obesity and MASH, with Phase 2 data showing substantial weight loss and liver improvements. It is not yet an approved medication, but the human pharmacology is well characterized for a pipeline drug.

## Pharmacokinetics

- **Model tier:** simple
- **Half-life:** 6.0 days (144 hours)
- **Bioavailability:** 80%

## Dosing

- **Default dose:** 4.8 mg
- **Typical range:** 0.72–9.6 mg
- **Units:** nmol/L

## Source

- **Label:** Estimated (limited public PK)
- **Notes:** Dual GLP-1/glucagon agonist; ~weekly half-life.

**Tags:** weight-loss, metabolic

---

**Canonical URL:** https://anabolicdex.com/compounds/survodutide
**Plot:** https://anabolicdex.com/plot?compound=survodutide